The myasthenia gravis market, valued at around $6 billion in 2025, is projected to grow at a 9.1% CAGR to surpass $16 billion by 2036. Growth is fueled by increasing diagnosed cases, especially among older populations, and a surge in innovative targeted therapies such as IMVT-1402, Descartes-08, and FABHALTA. Advances in diagnostics and a shift towards precision immunotherapy are transforming treatment approaches, with several promising drugs in late-stage trials expected to accelerate market expansion. This evolving landscape highlights significant opportunities for improved patient outcomes and commercial growth in the autoimmune disease sector.
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
The oligonucleotide drug development pipeline is rapidly expanding, featuring over 600 candidates from more than 200 companies including Novartis, Amgen, and Alnylam. These therapies target genetic diseases, cancers, and rare disorders using advanced...
